123 related articles for article (PubMed ID: 26186061)
1. Organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation.
Zhou R; Wu Q; Guo M; Huang W; He X; Yang L; Peng F; He G; Han B
Chem Commun (Camb); 2015 Aug; 51(66):13113-6. PubMed ID: 26186061
[TBL] [Abstract][Full Text] [Related]
2. Organocatalytic Asymmetric Synthesis of Spiro-oxindole Piperidine Derivatives That Reduce Cancer Cell Proliferation by Inhibiting MDM2-p53 Interaction.
Yang MC; Peng C; Huang H; Yang L; He XH; Huang W; Cui HL; He G; Han B
Org Lett; 2017 Dec; 19(24):6752-6755. PubMed ID: 29210587
[TBL] [Abstract][Full Text] [Related]
3. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors.
Wang S; Jiang Y; Wu S; Dong G; Miao Z; Zhang W; Sheng C
Org Lett; 2016 Mar; 18(5):1028-31. PubMed ID: 26883465
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
Zhang L; Ren W; Wang X; Zhang J; Liu J; Zhao L; Zhang X
Eur J Med Chem; 2017 Jan; 126():1071-1082. PubMed ID: 28027532
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
7. Core-Scaffold-Inspired Asymmetric Synthesis of Polysubstituted Chiral Hexahydropyridazines that Potently Inhibit Breast Cancer Cell Proliferation by Inducing Apoptosis.
Leng HJ; Peng F; Zingales S; Huang W; Wang B; Zhao Q; Zhou R; He G; Peng C; Han B
Chemistry; 2015 Dec; 21(50):18100-8. PubMed ID: 26498568
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
Kumar A; Gupta G; Bishnoi AK; Saxena R; Saini KS; Konwar R; Kumar S; Dwivedi A
Bioorg Med Chem; 2015 Feb; 23(4):839-48. PubMed ID: 25618595
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
10. Regio- and stereoselective synthesis of new spirooxindoles via 1,3-dipolar cycloaddition reaction: Anticancer and molecular docking studies.
Lotfy G; El Ashry ESH; Said MM; El Tamany ES; Abdel Aziz YM; Al-Dhfyan A; Al-Majid AM; Barakat A
J Photochem Photobiol B; 2018 Mar; 180():98-108. PubMed ID: 29413708
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
12. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities.
Rawat P; Verma SM
Drug Des Devel Ther; 2016; 10():2779-88. PubMed ID: 27621598
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
[TBL] [Abstract][Full Text] [Related]
18. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.
Huang Y; Wolf S; Beck B; Köhler LM; Khoury K; Popowicz GM; Goda SK; Subklewe M; Twarda A; Holak TA; Dömling A
ACS Chem Biol; 2014 Mar; 9(3):802-11. PubMed ID: 24405416
[TBL] [Abstract][Full Text] [Related]
19. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents.
Rahmani-Nezhad S; Safavi M; Pordeli M; Ardestani SK; Khosravani L; Pourshojaei Y; Mahdavi M; Emami S; Foroumadi A; Shafiee A
Eur J Med Chem; 2014 Oct; 86():562-9. PubMed ID: 25216378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
